File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jhep.2008.10.017
- Scopus: eid_2-s2.0-58149316191
- PMID: 19070393
- WOS: WOS:000263309000010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
Title | Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy |
---|---|
Authors | |
Keywords | Antiviral treatment Chronic hepatitis B Entecavir HBeAg-negative |
Issue Date | 2009 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep |
Citation | Journal Of Hepatology, 2009, v. 50 n. 2, p. 289-295 How to Cite? |
Abstract | Background/Aims: To evaluate the off-treatment durability of response in HBeAg-negative chronic hepatitis B patients who achieved a protocol-defined 'Response' (HBV-DNA < 0.7 MEq/mL and ALT < 1.25 × ULN) with entecavir at 48 weeks and the efficacy of entecavir in patients treated beyond one year. Methods: Entecavir-treated and lamivudine-treated patients who achieved a protocol-defined 'Response' were evaluated off-treatment for HBV-DNA < 300 copies/mL and ALT normalisation. Entecavir- and lamivudine-treated patients who achieved a protocol-defined 'Virological Response' (HBV-DNA < 0.7 MEq/mL but ALT ≥ 1.25 × ULN) at 48 weeks, continued blinded treatment until they achieved Response or 96 weeks, whichever came first. Results: Among 'Responders' who discontinued treatment after 48 weeks, 7/257 (3%) entecavir-treated and 10/201 (5%) lamivudine-treated patients sustained HBV-DNA below 300 copies/mL at 24-weeks off-treatment. Among the 54 patients who continued blinded treatment in the second year, 7/26 (27%) entecavir-treated and 6/28 (21%) lamivudine-treated patients normalised ALT and 22/26 (85%) entecavir-treated and 16/28 (57%) lamivudine-treated patients maintained HBV-DNA < 300 copies/mL at end-of-dosing. The safety profiles of both drugs remained comparable through a second year of treatment. Conclusions: The majority of protocol-defined Responders relapsed after 1 year when treatment was discontinued. Treatment with entecavir beyond 1 year provided continued virological and biochemical benefit. © 2008 European Association for the Study of the Liver. |
Persistent Identifier | http://hdl.handle.net/10722/163219 |
ISSN | 2023 Impact Factor: 26.8 2023 SCImago Journal Rankings: 9.857 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shouval, D | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Chang, TT | en_US |
dc.contributor.author | Cheinquer, H | en_US |
dc.contributor.author | Martin, P | en_US |
dc.contributor.author | Carosi, G | en_US |
dc.contributor.author | Han, S | en_US |
dc.contributor.author | Kaymakoglu, S | en_US |
dc.contributor.author | Tamez, R | en_US |
dc.contributor.author | Yang, J | en_US |
dc.contributor.author | Tenney, D | en_US |
dc.contributor.author | BrettSmith, H | en_US |
dc.date.accessioned | 2012-09-05T05:28:50Z | - |
dc.date.available | 2012-09-05T05:28:50Z | - |
dc.date.issued | 2009 | en_US |
dc.identifier.citation | Journal Of Hepatology, 2009, v. 50 n. 2, p. 289-295 | en_US |
dc.identifier.issn | 0168-8278 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163219 | - |
dc.description.abstract | Background/Aims: To evaluate the off-treatment durability of response in HBeAg-negative chronic hepatitis B patients who achieved a protocol-defined 'Response' (HBV-DNA < 0.7 MEq/mL and ALT < 1.25 × ULN) with entecavir at 48 weeks and the efficacy of entecavir in patients treated beyond one year. Methods: Entecavir-treated and lamivudine-treated patients who achieved a protocol-defined 'Response' were evaluated off-treatment for HBV-DNA < 300 copies/mL and ALT normalisation. Entecavir- and lamivudine-treated patients who achieved a protocol-defined 'Virological Response' (HBV-DNA < 0.7 MEq/mL but ALT ≥ 1.25 × ULN) at 48 weeks, continued blinded treatment until they achieved Response or 96 weeks, whichever came first. Results: Among 'Responders' who discontinued treatment after 48 weeks, 7/257 (3%) entecavir-treated and 10/201 (5%) lamivudine-treated patients sustained HBV-DNA below 300 copies/mL at 24-weeks off-treatment. Among the 54 patients who continued blinded treatment in the second year, 7/26 (27%) entecavir-treated and 6/28 (21%) lamivudine-treated patients normalised ALT and 22/26 (85%) entecavir-treated and 16/28 (57%) lamivudine-treated patients maintained HBV-DNA < 300 copies/mL at end-of-dosing. The safety profiles of both drugs remained comparable through a second year of treatment. Conclusions: The majority of protocol-defined Responders relapsed after 1 year when treatment was discontinued. Treatment with entecavir beyond 1 year provided continued virological and biochemical benefit. © 2008 European Association for the Study of the Liver. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep | en_US |
dc.relation.ispartof | Journal of Hepatology | en_US |
dc.subject | Antiviral treatment | - |
dc.subject | Chronic hepatitis B | - |
dc.subject | Entecavir | - |
dc.subject | HBeAg-negative | - |
dc.subject.mesh | Alanine Transaminase - Blood | en_US |
dc.subject.mesh | Antiviral Agents - Therapeutic Use | en_US |
dc.subject.mesh | Dna, Viral - Blood | en_US |
dc.subject.mesh | Double-Blind Method | en_US |
dc.subject.mesh | Drug Resistance, Viral | en_US |
dc.subject.mesh | Guanine - Analogs & Derivatives - Therapeutic Use | en_US |
dc.subject.mesh | Hepatitis B E Antigens - Blood | en_US |
dc.subject.mesh | Hepatitis B, Chronic - Drug Therapy - Virology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Lamivudine - Therapeutic Use | en_US |
dc.subject.mesh | Recurrence | en_US |
dc.subject.mesh | Viral Load | en_US |
dc.title | Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lai, CL:hrmelcl@hku.hk | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.jhep.2008.10.017 | en_US |
dc.identifier.pmid | 19070393 | - |
dc.identifier.scopus | eid_2-s2.0-58149316191 | en_US |
dc.identifier.hkuros | 181149 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-58149316191&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 50 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 289 | en_US |
dc.identifier.epage | 295 | en_US |
dc.identifier.isi | WOS:000263309000010 | - |
dc.publisher.place | Netherlands | en_US |
dc.identifier.scopusauthorid | Shouval, D=7006175997 | en_US |
dc.identifier.scopusauthorid | Lai, CL=7403086396 | en_US |
dc.identifier.scopusauthorid | Chang, TT=7404725147 | en_US |
dc.identifier.scopusauthorid | Cheinquer, H=6602829370 | en_US |
dc.identifier.scopusauthorid | Martin, P=7406037297 | en_US |
dc.identifier.scopusauthorid | Carosi, G=7102187567 | en_US |
dc.identifier.scopusauthorid | Han, S=8060394800 | en_US |
dc.identifier.scopusauthorid | Kaymakoglu, S=7004155395 | en_US |
dc.identifier.scopusauthorid | Tamez, R=25634823500 | en_US |
dc.identifier.scopusauthorid | Yang, J=15039392900 | en_US |
dc.identifier.scopusauthorid | Tenney, D=7006419890 | en_US |
dc.identifier.scopusauthorid | BrettSmith, H=7801442680 | en_US |
dc.identifier.issnl | 0168-8278 | - |